After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic versions of Novo Nordisk’s lucrative semaglutide drugs for diabetes and ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.

Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.

Neoadjuvant semaglutide showed no benefit in weight loss, diabetes remission or safety in a cohort of patients who underwent metabolic and bariatric surgery, according to study results published ...

Higher protein intake may be protective against muscle loss, which is tied to less improvement in glucose homeostasis.

Among patients with type 2 diabetes and peripheral artery disease or foot ulcers, the use of semaglutide is linked to a markedly lower risk for major limb events than the use of other glucose ...

Additionally, losing more lean mass was tied to less of an HbA1c reduction in the semaglutide group. Increasing protein intake may help preserve muscle mass for adults with obesity using semaglutide.

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a maintenance fee in 2019.

Low doses of the injectable weight-loss medication semaglutide may improve symptoms of a hard-to-treat type of heart failure. This effect happened through direct action on the heart muscle and ...

With their lengthening laundry list of health benefits, drugs like Ozempic are showing promise for people who struggle with addiction.

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 countries next year, the Indian drugmaker's CEO, Erez Israeli, said on ...